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Human cells express natural antiviral proteins, such
as APOBEC3G (A3G), that potently restrict HIV repli-
cation. As a counter-defense, HIV encodes the
accessory protein Vif, which binds A3G andmediates
its proteasomal degradation. Our structural knowl-
edge on how Vif and A3G interact is limited, because
a co-structure is not available. We identified specific
points of contact between Vif and A3G by using func-
tional assays with full-length A3G, patient-derived Vif
variants, and HIV forced evolution. These anchor
points were used to model and validate the Vif-A3G
interface. The resultant co-structure model shows
that the negatively charged b4-a4 A3G loop, which
contains primate-specific variation, is the core Vif
binding site and forms extensive interactions with a
positively charged pocket in HIV Vif. Our data present
a functional map of this viral-host interface and open
avenues for targeted approaches to block HIV repli-
cation by obstructing the Vif-A3G interaction.INTRODUCTION
APOBEC3G (A3G) is amember of the human APOBEC3 family of
seven cytidine deaminases (A3A–A3H) that act as restriction fac-
tors of HIV (Harris et al., 2003;Mangeat et al., 2003; Sheehy et al.,
2002; Zhang et al., 2003). In turn, HIV counteracts human A3G by
expressing the accessory Vif protein, which mediates the pro-
teasomal degradation of A3G by recruiting an E3 ubiquitin ligase
complex (Marin et al., 2003; Sheehy et al., 2003; Yu et al., 2003).
A3G consists of two deaminase domains: the catalytically inac-
tive N-terminal domain (NTD) contains the Vif binding site,
whereas the C-terminal domain has deaminase activity (Hache´
et al., 2005; Navarro et al., 2005). Despite the recently solved
structures of Vif and the NTD of A3G, no Vif-A3G co-structure ex-
ists to date (Guo et al., 2014; Kouno et al., 2015).
Strong reciprocal selection shaped the Vif-A3G interface dur-
ing primate evolution, and lentiviral restriction by A3G is species
specific. Previous studies showed that the A3G b4-a4 loop is
important for its Vif-mediated degradation. This loop containsCell Rethree residues 128-DPD-130 that are variable among primates
and confers a species-specific barrier for transmission (Fig-
ure 1A) (Bogerd et al., 2004; Bulliard et al., 2009; Compton and
Emerman, 2013; Compton et al., 2012; Huthoff and Malim,
2007; Letko et al., 2013; Mangeat et al., 2004; Schro¨felbauer
et al., 2004; Xu et al., 2004). For example, human A3G-128D
and African green monkey A3G-128K are both efficiently coun-
teracted by the Vif of their cognate lentiviruses, HIV-1 and simian
immunodeficiency virus (SIV) African green monkey (SIVagm),
respectively. This phenotype can be fully reversed by changing
A3G-128D of the human A3G to a lysine, indicating that Vif spe-
cifically binds A3G at this position (Bogerd et al., 2004; Mangeat
et al., 2004; Schro¨felbauer et al., 2004; Xu et al., 2004). In addi-
tion, gorillas encode A3G-129Q, which confers resistance to
SIV chimpanzee (SIVcpz), HIV-1, and HIV-2 Vif (Letko et al.,
2013). The block to infection associated with the gorilla A3G-
129Q is lost by ‘‘humanizing’’ the gorilla A3G to 129P (D’arc
et al., 2015; Letko et al., 2013).
Numerous Vif residues throughout the N-terminal part of Vif
have been implicated in counteracting A3G (see Figure 1A and
the summary in Table S1). Mutating Vif amino acids 22, 26, 40–
44, and 70 specifically abrogates A3G degradation, indicating
that these Vif residues are required for A3G recognition (as sum-
marized in Table S1). These residues are not implicated in de-
grading A3C, A3F, and A3H, suggesting that Vif uses distinct
binding sites for different APOBEC3 proteins (as reviewed in
Desimmie et al., 2014 and Salter et al., 2014).
In contrast, our knowledge about specific Vif-A3G interactions
is limited. Only one study demonstrated a direct point of interac-
tion between Vif and A3G (Schro¨felbauer et al., 2006). A human
A3G-D128K mutant cannot be counteracted by HIV-1 Vif but is
efficiently degraded by SIVagm Vif. Mutating HIV-1 Vif-14-
DRMR-17 to Vif-14-SEMQ-17 enabled the mutant HIV-1 Vif to
degrade A3G-128K, suggesting that Vif-14–17 and A3G-128
interact (Figure 1B) (Schro¨felbauer et al., 2006). However, a sin-
gle point of contact between Vif and A3G is not sufficient to
correctly orient the two proteins (Figure 1B).
Structural approaches such as nuclear magnetic resonance
(NMR) or crystallography are traditionally used to solve pro-
tein-protein interfaces but face technical limitations with protein
complexes that are difficult to purify, such as HIV Vif and A3G.
We hypothesized that the Vif-A3G interface could be mapped
using viral restriction as a readout. This approach has theports 13, 1789–1799, December 1, 2015 ª2015 The Authors 1789
Figure 1. HIV-1 Vif and A3G Amino Acid Pair Mapping to Determine the Vif-A3G Interface
(A) A3G amino acids 128, 129, and 130 in the NTD confer sensitivity to Vif-mediated degradation. A large part of the N-terminal part of Vif (1–91) is implicated in
counteracting A3G. A3G-128 directly interacts with Vif-14–17. See also Table S1.
(B) The interaction between A3G-128 and Vif-14–17 is insufficient to accurately model the Vif-A3G interaction.
(C) An overview shows the Vif-A3Gmapping approach. Vif binds A3G and leads to its proteasomal degradation (scenario I). Specific A3Gmutations in the Vif-A3G
interface abrogate Vif binding; hence, the Vif-resistant A3G mutant is not degraded by Vif (scenario II). By identifying Vif variants that can counteract the Vif-
resistant A3G, one can pinpoint which Vif residues specifically interact with the Vif-resistant A3G (scenario III).
(D) Increasing levels of WT A3G (0, 5, 10, 25, 50, and 100 ng; left panel) and A3G-128K (right panel) were co-transfected with HIV DVif and in the presence of WT
NL4-3 Vif or Vif-14-SEMQ-17. Viral infectivity was assessed by TZM-bl reporter cells. 293T cell lysates were analyzed by western blot. Error bars represent SDs
from triplicate transfections.
(E) WT and 14-SEMQ-17 NL4-3 Vifs were co-transfected with WT A3G or A3G-128K and immunoprecipitated with aHA beads. Proteins were analyzed by
western blot.
(F) Our data indicate that A3G-128 is close to Vif-14–17.advantage of relying on full-length, functional viral and host pro-
teins. It is based on the disruption of the Vif-A3G interface by
specific A3G mutations and the subsequent identification of Vif
mutations that specifically restore viral rescue (Figure 1C). We
successfully employed this strategy to identify three specific
Vif-A3G points of contact. The resultant Vif-A3G co-structure
model indicates that the b4-a4 A3G loop fits into a well-defined
pocket on the surface of Vif and explains why this loop contains
extensive primate-specific variation.
RESULTS
Intracellular Protein Structure Probing to Determine the
Vif-A3G Interface
We propose that the interface between host defense proteins
such as A3G and the corresponding lentiviral antagonist Vif
can be accurately modeled by using A3G antiviral activity as a
readout (Figure 1C). HIV-1 Vif binds A3G, which leads to its pro-
teasomal degradation (scenario I, no antiviral activity). Specific
A3G mutations in the Vif-A3G interface abrogate Vif binding,
and A3G is not degraded (scenario II, strong antiviral activity).1790 Cell Reports 13, 1789–1799, December 1, 2015 ª2015 The AutScreening natural Vif variants or adapting HIV to counteract the
Vif-resistant A3G allows identification of Vif mutants that accom-
modate the A3G mutant (scenario III, no antiviral activity). We
anticipate that the accommodating Vif residue has properties
(e.g., charge or size) opposite those of the A3G mutation. These
functional Vif-A3G interaction pairs can be used as anchor points
to model the Vif-A3G interface, with three contact points
required to correctly orient both proteins. Only A3G and Vif mu-
tants that are functionally active and thus properly folded were
used in this study. All A3G mutants restricted HIV in the absence
of Vif, and all Vif mutants counteracted either a wild-type (WT)
A3G or a mutant A3G or A3F.
First Point of Contact: A3G-128 Interacts with Vif-14–17
For the first point of contact, we built on the observation that the
HIV Vif-resistant mutant A3G-128K is counteracted by a Vif-14-
SEMQ-17 mutant (Schro¨felbauer et al., 2006). We confirmed this
observation by testing the restriction of WT NL4-3, NL4-3 Vif-14-
SEMQ-17, and NL4-3 DVif with increasing amounts of WT A3G
and the mutant A3G-128K. In the absence of Vif, A3G potently
restricted HIV, and infectivity was rescued by degradation ofhors
Figure 2. A3G-125R Confers Resistance to HIV-1 Vif
(A) Twenty-two arginines were individually introduced in the NTD of A3G at the indicated positions.
(B) The arginine mutants were modeled onto the predicted NTD of A3G.
(C) The single-cycle infectivity assay has the A3G arginine mutants, A3G-128K, WT A3G, and a panel of subtype Vifs. The average infectivity values of a triplicate
transfection are shown as a heatmap, where no restriction is indicated in blue and potent restriction is shown in red.
(D) Single-cycle infectivity assays with an increasing amount of WT A3G and A3G-125R (0, 5, 10, 25, 50, and 100 ng) in the absence (left panel) or in the presence
(right panel) of NL4-3 Vif. 293T cell lysates were analyzed by western blot. Error bars represent SDs from triplicate transfections.A3G in the presence of WT Vif and Vif-14-SEMQ-17 (Figure 1D,
left panel). However, A3G-128K was only counteracted by Vif-
14-SEMQ-17 (Figure 1D, right panel), not by WT Vif, which is in
full agreement with the previous study (Schro¨felbauer et al.,
2006). We speculate that the large positively charged arginines
in WT Vif-14-DRMR-17 specifically clash with the positively
charged lysine of A3G-128K, which is compensated for by the
smaller negatively charged glutamate in Vif-14-SEMQ-17. Vif-
14-SEMQ-17 was also able to counteract WT A3G-128D,
possibly due to the smaller size of the glutamate and aspartate,
respectively. Co-immunoprecipitation (coIP) assays with WT
A3G and A3G-128K with WT Vif and Vif-14-SEMQ-17 showed
that WT Vif was only efficiently pulled down with WT A3G while
Vif-14-SEMQ-17 efficiently interacted with both WT A3G and
A3G-128K (Figure 1E). Taken together, our data indicate that
residues Vif-14–17 are close to A3G-128 (Figure 1F).
Second Point of Contact: A3G-125R Confers Resistance
to HIV-1 Vif
To identify A3G residues that confer resistance to Vif-mediated
degradation, we performed an arginine scan of surface exposed
a helixes, b strands, and loops of the NTD of A3G (Figures 2A and
2B). We chose arginine—over the commonly used alanine—
mutagenesis because a bulky and charged arginine would
more efficiently perturb the interaction with Vif. We tested the
antiviral activity and Vif sensitivity of 22 A3G argininemutants us-
ing a HIV subtype Vif panel (Figure 2C) (Binka et al., 2012). In the
absence of Vif, all A3G mutants restricted HIV to levels similar to
that of WT A3G and A3G-128K, indicating they are fully func-Cell Retional (Figure 2C).Whilemost A3Gmutants were efficiently coun-
teracted by the Vif variants, the mutant A3G-125R was resistant
to Vif, similar to the A3G-128K variant (Figure 2C). A3G residue
125, although close to residue 128, has not previously been
implicated in resistance to Vif. Only one Vif of HIV subtype D
(D2) could partially counteract A3G-125R (Figure 2C). Titrating
WT A3G and A3G-125R restrict to similar levels in the absence
of Vif (Figure 2D, left panel). However, onlyWT A3Gwas counter-
acted by Vif, whereas A3G-125R was fully resistant to Vif-medi-
ated degradation (Figure 2D, right panel).
Second Point of Contact: Vif Amino Acids 19 and 22
Determine Activity against A3G-125R
Next, we designed a series of experiments to find a Vif variant
that counteracts A3G-125R. We therefore cloned a panel of 66
HIV subtype B Vif alleles from 35 chronically infected, untreated
participants of the Amsterdam Cohort Studies (ACS) into full-
length NL4-3 (Kootstra et al., 2007). The variants differed by
7%–16% at the amino acid level and were tested in single-cycle
infectivity assays in the presence ofWT A3G or A3G-125R. In the
absence of Vif (DVif), WT A3G potently restricted HIV but was
efficiently counteracted by all Vif variants (Figure 3A, top). In
contrast, most Vif variants failed to counteract A3G-125R, but
some Vifs were able to counteract A3G-125R (Figure 3A, bot-
tom). A comparison of the infectivity values in the presence of
WT A3G and A3G-125R showed that 14 of 66 Vifs had activity
against A3G-125R (Figure 3B). An analysis of the amino acid dif-
ferences between the 52 inactive and the 14 active Vif variants by
viral epidemiology signature pattern analysis (VESPA) (Rose andports 13, 1789–1799, December 1, 2015 ª2015 The Authors 1791
Figure 3. Vif Screening Identifies Vif Positions 19 and 22 to Confer Activity to A3G-125R
(A) Sixty-six patient-derived Vifs and LAI, NL4-3, and an inactive Vif were cloned into full-length NL4-3 and were tested in single-cycle infectivity assays in the
presence of WT A3G (top panel) or A3G-125R (bottom panel). Error bars represent SDs from triplicate transfections.
(B) The infectivity values in the presence of A3G-125R were divided by the infectivity values measured in the presence of WT A3G. The Vifs that can (in green) or
cannot (in black) counteract A3G-125R are indicated.
(C) The frequency of the most abundant amino acid at each position of the Vifs able to counteract A3G-125R was divided by the amino acid frequency of the
inactive Vifs using VESPA (Rose and Korber, 2000).
(D) A weblogo plot of amino acids 14–27 shows the Vifs that fail to counteract A3G-125R (top) and the Vifs that efficiently counteract A3G-125R (bottom). See also
Figure S1.
(E) Vif positions 19 and 22 are indicated in green on the Vif crystal structure. Both residues are close to Vif-14–17 (pink).Korber, 2000) pointed to Vif position 19 as being the most
different (Figure 3C). An amino acid weblogo representation
showed that Vifs unable to counteract A3G-125R encode either
Vif-19R or Vif-19K (R: 45/52 and K: 7/52) (Figure 3D). In contrast,
the Vifs that are active against A3G-125Rmore often encode Vif-
19S (S: 9/14, R: 4/14, and K: 1/14). However, the Vif activity
cannot be fully explained by only Vif residue 19, because five
Vifs with activity against A3G-125R encode an arginine or lysine
at this position (e.g., R: 4/5 and K: 1/5). We therefore shifted our
attention to nearby Vif position 22, which was also variable (Fig-
ure 3D). The Vifs that failed to counteract A3G-125R typically en-
coded Vif-19R and Vif-22K (19R+22K: 40/52, 19K+22K: 7/52,
19R+22N: 2/52, and 19R+22H: 3/52), while Vifs with activity
against A3G-125R never encoded bulky and charged resi-
dues such as arginine and lysine at both positions (19S+22K:
9/14, 19R+22N: 2/14, 19R+22H: 1/14, 19R+22V: 1/14, and
19K+22N: 1/14) (Figure 3D; Figure S1). These functional data
suggest that the presence of two bulky positively charged argi-
nines and lysines at Vif positions 19 and 22 would be incompat-
ible with counteracting A3G-125R. Conversely, Vif counteracts
A3G-125R if one of these two Vif residues (19 or 22) was not
an arginine or a lysine and preferably encodes Vif-19S or Vif-
22N, Vif-22H, or Vif-22V (Figure S1). Vif residues 19 and 22 are
close to the 14–17 stretch and potentially represent a second
point of contact between Vif and A3G (Figure 3E).1792 Cell Reports 13, 1789–1799, December 1, 2015 ª2015 The AutWe next performed loss-of-function and gain-of-function ex-
periments using Vifs that can or cannot counteract A3G-125R.
We selected four Vifs with activity against A3G-125R, encoding
either a lysine at Vif position 19 or an arginine at position 22,
and we introduced a second arginine or lysine at position 19 or
22 (Figure 4A). TheWT patients’ Vif variants degraded and coun-
teracted A3G-125R, but the mutant Vifs lost activity against
A3G-125R (Figure 4B, left). The loss of activity of the Vif mutants
was specific for A3G-125R, because activity against WT A3G re-
mained unchanged (Figure 4B, right).
For the gain-of-function experiments, we used HIV-1 LAI Vif,
which encodes an arginine and a lysine at positions 19 and 22,
respectively, and did not counteract A3G-125R (Figures 2C
and 3B). We mutated position 19 to a serine and position 22 to
a valine individually or in combination (Figure 4C). LAI WT Vif
showed little activity against A3G-125R, but LAI Vif-19S and
Vif-22V displayed increased A3G-125R degradation (Figure 4D,
left). Moreover, the double mutant, Vif-19S+22V, efficiently
degraded and counteracted A3G-125R (Figure 4D). The effect
of the single mutations at positions 19 and 22 of Vif was specific
for A3G-125R, and the double mutant lost its activity against WT
A3G (Figure 4D, right), indicating specific interactions between
Vif positions 19 and 22 and A3G position 125. CoIP experiments
showed that individual or combined Vif mutations at positions 19
and 22 improved the association of Vif with A3G-125Rhors
Figure 4. A3G Position 125 Interacts with Vif Amino Acids 19 and 22
(A) Four patient-derived Vifs that counteract A3G-125R and do not encode an arginine or lysine at both position 19 and position 22 were mutated to 19R and 22K.
(B) The four patient Vifs and their respective mutants were tested in single-cycle infectivity assays in the presence of A3G-125R (left panel) and WT A3G (right
panel), and 293T cell lysates were analyzed by western blot. Error bars represent SDs from triplicate transfections.
(C and D) LAI Vif (C), which encodes 19R and 22K and does not counteract A3G-125R, was mutated at positions 19 and 22 with the indicated residues. Antiviral
activity of these Vif mutants was tested in the presence of A3G-125R (D, left panel) or WT A3G (D, right panel). 293T cell lysates were analyzed by western blot.
Error bars represent SDs from triplicate transfections.
(E) IPs were performed with WT LAI Vif and its 19 and 22 mutants and with WT A3G or A3G-125R. Proteins were analyzed by western blot.
(F) Combined, our data show that Vif-19+22 interacts with A3G-125. See also Figure S2.(Figure 4E). In contrast, the Vif-19S+22V double mutant showed
reduced interaction with WT A3G, an observation that is in good
agreement with its inability to degrade WT A3G (Figure 4D).
Our observation that Vif-19S+22V degraded A3G-125R but
not WT A3G indicates that the interaction between these resi-
dues is specific. Human and chimpanzee A3G always encode
125Y, and the combined absence of arginines or lysines at Vif
positions 19 and 22 (e.g., Vif-19S+22V) is never observed in
natural HIV-1 and SIVcpz Vif sequences (Figure S2A). The sub-
type D Vif variant (Vif-D2) (Figure 2C), which had partial activity
against A3G-125R, was the only Vif in the subtype panel to
encode Vif-19S (Figure S2B).
Combined, our data indicate a specific interaction between
the Vif residues 19 and 22 and the A3Gamino acid at position 125
(Figure 4F).
Third Point of Contact: A3G Position 130 Interacts with
Vif Position 82
To obtain the third specific Vif-A3G pair, we focused on A3G po-
sition 130, which was shown to be important for Vif-mediated
degradation (Bulliard et al., 2009; Compton and Emerman,
2013; Compton et al., 2012; Huthoff and Malim, 2007). In the
absence of Vif, both WT and the A3G-130R mutant potentlyCell Rerestricted HIV (Figure 5A), and A3G-130R resisted Vif-mediated
degradation and efficiently inhibited HIV (Figure 5A). To find Vif
variants that naturally counteract A3G-130R, we first tested
our subtype and patient-derived Vif panels against A3G-130R.
However, all tested Vifs failed to counteract A3G-130R (data
not shown).
As an alternative approach to acquire Vif mutants that can
counteract A3G-130R, we conducted forced evolution experi-
ments. We generated stable cell lines of permissive SupT1
T cells expressing A3G, GFP, and puromycin N-acetyltrans-
ferase separated by P2A and T2A ‘‘self-cleaving’’ peptides
(Figure 5B). The combined expression of A3G with GFP and pu-
romycin N-acetyltransferase ensures that all puromycin-resis-
tant cells express GFP and A3G. The four cell lines expressed
WT A3G, a catalytically inactive A3G (E67A+E259A), A3G-
130R, and A3G-128K to levels comparable to endogenously
expressed A3G in the non-permissive T cell lines H9 and
MT2 (Figure 5B). The A3G proteins are slightly larger due to
the addition of the P2A peptide. The cell lines were infected
with HIV-1 NL4-3, and replication was monitored over 2 weeks.
HIV replication was robust on the cells expressing WT A3G
and the A3G catalytic mutant, whereas viral replication
was restricted on cells expressing A3G-130R and A3G-128Kports 13, 1789–1799, December 1, 2015 ª2015 The Authors 1793
Figure 5. A3G Position 130 Interacts with Vif Position 82
(A) HIV DVif was co-transfected with either WT A3G or A3G-130R in the presence or absence of NL4-3 Vif. Infectivity was measured by infecting TZM-bl reporter
cells. 293T cell lysates were analyzed by western blot. Error bars represent SDs of triplicate transfections.
(B) A schematic overview shows the lentiviral A3G expression cassette. The transduced cells were lysed and probed for A3G protein expression. The asterisk
indicates the inactive A3G, which contains two inactivating mutations in both catalytic sites (E67A+E259A). The non-permissive T cell lines H9 and MT2 both
endogenously express A3G.
(C) The SupT1 cell lines expressing WT A3G, the inactive A3G deaminase mutant, A3G-130R, and A3G-128K were infected with NL4-3, and supernatants were
harvested each day and checked for infectivity on TZM-bl reporter cells. Error bars represent SDs of three separate infections.
(D) SupT1 cells expressing A3G-130R were infected with NL4-3 and maintained for 8 weeks, and Vif was PCR amplified and sequenced from proviral DNA
isolated 6 and 8 weeks post-infection. The chromatograms show a mixed population of Vif-82G/D after 6 weeks, and Vif-82D represent most viruses 8 weeks
post-infection.
(E) Vif position 82 is indicated in green on the Vif crystal structure and is close to Vif-14–17 and Vif-19+22 (pink).
(F) WT and 82D Vifs were tested with A3G-130R and WT A3G in single-cycle infectivity assays. The 293T cell lysates were analyzed by western blot. Error bars
represent SDs from triplicate transfections.
(G) Vif-82D and Vif-82K were cloned into full-length NL4-3, and viruses were produced in 293T and used to infect SupT1 cells expressing empty vector, WT A3G,
or A3G-130R. Supernatants were harvested each day and checked for infectivity on TZM-bl reporter cells. Error bars represent SDs of three separate infections.
(H) IPs were performed with WT NL4-3 Vif and Vif-82D and WT A3G or A3G-125R, and proteins were analyzed by western blot.
(I) Combined, our data show that WT Vif-82G and Vif-82K interact with A3G-130D and that Vif-82D specifically interacts with A3G-130R, indicating that Vif-82
interacts with A3G-130. See also Figure S3.(Figure 5C). Long-term culturing of the infected A3G-130R-ex-
pressing cells showed syncytia after 8 weeks, indicative of pro-
ductive viral replication, and revealed the emergence of a viral
strain encoding a Vif-G82D substitution (Figure 5D). No other
Vif changes were observed.
Vif position 82 is close to positions 14–17 and 19+22, indi-
cating that Vif position 82 could represent a direct contact point
for A3G position 130 (Figure 5E). Single-cycle infectivity assays
showed that Vif-82D displayed improved activity against A3G-
130R, while its activity against WT A3G was slightly reduced
compared to the WT Vif (Figure 5F).
Next, we tested the fitness of Vif-82D in T cells expressing WT
A3G or A3G-130R. We included Vif-82K to test whether the posi-
tively charged lysine would further obstruct binding with A3G-
130R. All three viruses replicated similarly in the absence of
A3G (Figure 5G, top). WT and Vif-82K viruses replicated effi-1794 Cell Reports 13, 1789–1799, December 1, 2015 ª2015 The Autciently in the presence of WT A3G, while Vif-82D showed
delayed replication (Figure 5G, middle). In contrast, NL4-3 Vif-
82D was the only virus able to replicate efficiently on SupT1
expressing A3G-130R (Figure 5G, bottom). The Vif-82K virus
was even more restricted on A3G-130R-expressing cells than
WT HIV (Figure 5G, bottom). This suggests that identically
charged amino acids at A3G position 130 and Vif position 82 per-
turbate the Vif-A3G interaction and can be restored by intro-
ducing residues with opposite charges.
CoIPs showed a diminished interaction between A3G-130R
and WT Vif, which was restored for Vif-82D (Figure 5H). In
contrast, both Vif variants interacted efficiently with WT A3G.
The importance of WT Vif-82G is further underscored by
its extreme conservation among all HIV-1 and SIVcpz Vifs (Fig-
ure S3). Combined, our data indicate that A3G position 130 inter-
acts with Vif position 82 (Figure 5I).hors
Figure 6. Vif-A3G Contact Point Specificity and Mapping the A3G Binding Surface of Vif
(A–C) HIVDVif was co-transfected withWT A3G, A3G-125R, A3G-128K, or A3G-130R in the presence or absence of Vif WT, Vif-19S+22V, Vif-82D, Vif-14-SEMQ-
17, Vif-15E, and Vif-15A. Infectivity was measured by infecting TZM-bl reporter cells. Error bars represent SDs from triplicate transfections.
(D) Vif residues around Vif-14–17, Vif-19+22, and Vif-82 weremutated to the indicated amino acids andwere tested against A3G and A3F in single-cycle infectivity
assays. The average infectivity values of a triplicate transfection are shown as a heatmap, where no restriction is indicated in blue and potent restriction is shown
in red.
(E) The results from (A) are mapped onto the Vif crystal structure. Vif-14–17, Vif-19+22, and Vif-82 are indicated in pink; the Vif residues important for coun-
teracting A3G are indicated in orange; and Vif residues that do not affect counteracting A3G are shown in green. Vif residues 79 and 80 are specifically required for
counteracting A3F.
(F) The electrostatic potential of Vif and A3G were analyzed by the APBS tool in PyMOL using standard settings.Vif-A3G Contact Point Specificity and Mapping the A3G
Binding Surface of Vif
To confirm the specificity of the three points of interaction and
exclude indirect structural changes, we assessed the infectivity
of HIV produced in the presence of different A3G and Vif variants.
Vif-19S+22V only counteracted A3G-125R, not WT A3G, A3G-
128K, and A3G-130R, indicating that the interaction between
A3G-125 and Vif-19+22 is specific (Figure 6A). In addition, Vif-
82D specifically counteracted A3G-130R efficiently but failed
to rescue infectivity with A3G-125R or A3G-128K, suggesting a
specific interaction (Figure 6B). However, Vif-14-SEMQ-17 was
able to counteract all three A3G mutants, which indicates an
aspecific effect (Figure 6C). Because we hypothesized that
A3G-128D and A3G-128K would interact with Vif-15R and Vif-
15E, respectively, we tested two additional Vif mutants, Vif-
15E and Vif-15A, for their activity against the A3G mutant panel.
Vif-15E counteracted the different A3G mutants, similarly to Vif-
14-SEMQ-17, indicating that only Vif position 15 plays a role in
binding to A3G positions 125, 128, and 130 (Figure 6C). Vif-
15A could not counteract A3G-128K yet maintained activity
against A3G-125R and A3G-130R, indicating that the negative
charge of the glutamate is required for the interaction with
A3G-128K (Figure 6C). Combined, our data suggest that in the
Vif-A3G interface, A3G-125 must be close to Vif residues 19
and 22, A3G-130 is close to Vif-82, and Vif-15 is close to A3G-
128 but also close to A3G-125 and A3G-130 (summarized in
Table S2).Cell ReNext, we performed extensive mutagenesis of Vif residues
located structurally close to the Vif residues 14–17, 19+22, and
82 to further define the A3G binding site of Vif. Vif mutants
were tested against A3G, as well as A3F, to minimize erroneous
conclusions caused by Vif misfolding or failure to interact with E3
ligase components. Only Vif mutations that resulted in a selective
loss of activity against A3G or A3F, but not both, were interpreted
as being specific binding sites. Mutating Vif residues 26, 40, 42,
43, 44, 45, 52, and 70 resulted in a loss of A3G recognition but
not against A3F, indicating that these residues are specifically
involved in A3G binding, which is in agreement with previous
studies (Figures 6D and 6E, indicated in orange) (Chen et al.,
2009; Dang et al., 2009; He et al., 2008; Mehle et al., 2007; Rus-
sell and Pathak, 2007; Simon et al., 2005). Vif residues 40-
YRHHY-44 have been previously implicated to be specifically
required for counteracting A3G (Russell and Pathak, 2007).
Mutating Vif at positions 18, 23, 27, 29, 31, 39, 41, 46, 47, and
53 did not affect A3G or A3F counteraction, suggesting that
these residues are not interacting with A3G or A3F (Figure 6E,
indicated in green). Mutating Vif positions 79 or 80 resulted in a
specific loss of activity against A3F but not A3G, suggesting
that these residues are required for interaction with A3F (Fig-
ure 6E) (He et al., 2008). Combined, our data show that the Vif re-
gion required for counteracting A3G forms a defined pocket that
consists of Vif residues 14–17, 19+22, and 82 on one side and Vif
residues 26, 40, 42, 43, 44, 45, and 70 on the opposite side
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Figure 7. The b4-a4 A3G Loop Fits in the Positively Charged Pocket of Vif
(A) The model of the NTD of A3G was based on the A3C crystal structure and was submitted with the Vif crystal structure to ZDock protein docking software.
Structures were visually inspected, and a structure that fits our experimental data is shown. See also Figure S4.
(B) Individual close ups of the Vif-A3G structure model show a close interaction of Vif-14–17 with A3G-128 (left), A3G-125 is located between Vif-19 and Vif-22
(middle), and A3G-130 and Vif-82 are close (right).
(C) Individual close up of the Vif-A3G structure model shows a close interaction with Vif-15R with A3G-125, A3G-128, and A3G-130.
(D) A schematic overview shows the relative distances between A3G residues 125, 128, and 130 and Vif residues 15, 19, 22, and 82.
(E) A close up of the Vif-A3G structure model indicates that the A3G b4-a4 loop between fits in the Vif pocket flanked by Vif-14–17 and Vif-19+22 on one side and
Vif-40–44 on the other side.
(F) The docked Vif-A3Gmodel is shown in context with the E3-ligase components elongin B, elongin C, and the transcription co-factor CBF-b from the published
Vif-crystal structure (4N9F). The structure for full-length Cullin-5 was predicted from the available structural data for Cullin-1 and Cullin-5. Spheres representing
approximate sizes and locations for the A3G-C-terminal domain, Rbx2, and E2 ubiquitin conjugating enzyme are shown in red, purple, and green, respectively.
Ubiquitin is shown in white.
(G) An overview shows primate-specific A3G polymorphisms in the A3G b4-a4 loop and their sensitivity to Vif proteins from different primates. The three amino
acids at A3G positions 128, 129, and 130 are indicated. African greenmonkeys encode different A3G loop variants depending on their species subtypes. The red
squares indicate that the Vif protein cannot counteract the specific primate A3G, and the white squares represent efficient counteraction by Vif.Electrostatic forces play a crucial role in interactions between
proteins (Baker et al., 2001). We therefore mapped the electro-
static potentials of both Vif and A3G. The Vif pocket has a posi-
tive electrostatic potential, whereas the A3G b4-a4 loop has a
negative electrostatic potential, which would favor a direct inter-
action between Vif and A3G (Figure 6F).
The b4-a4 A3G Loop Fits in the Positively Charged
Pocket of Vif
To predict how Vif and A3G interact, we applied protein docking
with the crystal structure of Vif and an NTD model of A3G based
on the A3C crystal structure. The A3Gmodel we used is structur-
ally similar to the recently published A3G-NTD NMR structure
(Figure S4A) (Kouno et al., 2015). Vif-A3G structures were pre-
dicted using ZDock software (Pierce et al., 2014), with con-
straints to align the three Vif-A3G contact points, and predictions
were individually inspected. Of 18 predictions, five similar struc-
tures fit our three Vif-A3G contact points (Figure 7A; Figure S4B).
In these models, A3G-128K is close to Vif-14DRMR-17, with Vif-
15 interacting with A3G-128 (Figure 7B), which is in agreement1796 Cell Reports 13, 1789–1799, December 1, 2015 ª2015 The Autwith the specificity experiments (Figures 6A–6C). Furthermore,
A3G-125Y is positioned between Vif-19N and Vif-22K, and
A3G-130D is next to Vif-82D.
A closer inspection of our Vif-A3G structure model shows that
Vif-15 is close to A3G positions 125, 128, and 130 (Figure 7C),
which explains the why Vif-15E efficiently counteracted A3G-
125R, A3G-128K, and A3G-130R (Figure 6C). We speculate
that A3G-128 can only interact with Vif position 15 and that their
interaction is efficient as long as their charges are opposite. In
contrast, A3G-125 and A3G-130 have more structural flexibility
and can both interact with Vif position 15 but can only individually
interact with Vif-19+22 and Vif-82, respectively (Figures 7C and
7D). Our model reveals not only that the b4-a4 A3G loop, which
contains A3G positions 125, 128, and 130, fits in the Vif pocket
but also that other A3G b4-a4 loop residues, such as 124, 127,
129, and 131, interact with Vif residues lining the pocket, under-
scoring the importance of the A3G b4-a4 loop as the core bind-
ing site of Vif (Figure 7E). By using our Vif-A3G structure model,
we can detect other potential points of contact between Vif
andA3G, such as theA3G loops between a helix 1 and b strand 1,hors
a helix 2 and b strand 2, and b strand 3 and a helix 3 (Figures S4C
and S4D), which is in good agreement with a recent A3G NMR
study (Figure S4E) (Kouno et al., 2015).
Next, we integrated our Vif-A3G interaction model in the
context of the entire E3-ligase complex by using the crystal struc-
ture of Vif, core-binding factor subunit beta (CBF-b), Elongin B
and C, and the N-terminal part of Cullin-5, and we modeled the
missing C-terminal part of Cullin-5 based on an existing Cullin-1
crystal structure (Goldenberg et al., 2004; Guo et al., 2014).
Because the orientation of the C-terminal A3G domain to the
NTD remains unknown,we represent theC-terminal A3Gdomain
as a sphere placed at the end of the N-terminal A3G domain. This
shows that A3G binding to Vif does not overlap with other pro-
teins such as CBF-b and Elongin C binding (Figure 7F). Further-
more, our model predicts that the C-terminal domain of A3G is
oriented toward the currently unknown E2 ligase, which is the
main target for ubiquitination (Iwatani et al., 2009).
In summary, the identification of three specific points of con-
tact between Vif and A3G, in combination with extensive Vif
mutagenesis, allowed us to generate an in vivo Vif-A3G protein
interaction model.
DISCUSSION
Despite extensive research on HIV-1 Vif and A3G, a co-structure
of this viral host interface remains elusive. We mapped the Vif-
A3G interface by disrupting Vif-A3G interactions and identifying
Vif mutations that specifically restore viral rescue. The strength
of our approach is the use of full-length intracellular proteins in
functional assays. Our approach identified three points of con-
tact and generated a Vif-A3G interaction model, which explains
previous reports of Vif mutagenesis.
Our Vif-A3G structuremodel indicates that the A3G b4-a4 loop
fits into a well-defined pocket on the surface of Vif. A3G loop b4-
a4 residues 128, 129, and 130 have been under positive selec-
tion during primate evolution, and primate-specific variants can
block the transmission of SIV or HIV from other primates (Bogerd
et al., 2004; Compton and Emerman, 2013; Compton et al.,
2012; Letko et al., 2013; Mangeat et al., 2004; Schro¨felbauer
et al., 2004; Xu et al., 2004). The primate-specific b4-a4 loop
changes and their effects on SIV/HIV restriction are summarized
in Figure 7G. The Vif proteins of SIV or HIV counteract the A3G of
their natural host, but the viruses are restricted by other primate
A3G variants with b4-a4 loop changes. Gorilla A3G, which en-
codes 129Q, is resistant to all SIV and HIV variants except SIV
gorilla (Letko et al., 2013). Our interaction model underscores
that the A3G b4-a4 loop represents the core Vif binding site
and may explain why species-specific variation in this relatively
small loop determines primate-species tropism.
We chose to use an N-terminal A3G domain homology model
based on an A3C crystal structure because all APOBEC3 do-
mains are structurally similar. Recently, the NMR structure of
the Vif binding NTD of A3Gwas solved (Kouno et al., 2015). How-
ever, the N-terminal A3G domain used in that study lacks anti-
viral activity due to the 30 substitutions or deletions needed to
increase its solubility. Our modeled A3G NTD is nonetheless in
good agreement with this NMR structure (Figure S4A, top)
(Kouno et al., 2015). The b4-a4 loop, containing A3G-125,Cell ReA3G-128, and A3G-130 varies considerably between NMR
structures, suggesting some structural flexibility (Figure S4A,
bottom) (Kouno et al., 2015).
Previous studies identified numerous amino acids in Vif to be
important for binding to A3G (Figure 1A; Table S1). However,
our Vif mutagenesis and Vif-A3G interface model suggest that
the A3G binding site of Vif is limited to a well-defined pocket
located on one side of Vif (Figure 6E). We speculate that some
Vif residues located outside of this defined Vif pocket area are
not involved in A3G binding but lead to Vif misfolding or affect,
e.g., binding to CBF-b (Table S1). Therefore, Vif mutants should
be tested against other APOBEC3 proteins, such as A3F, which
uses another Vif binding site to ensure functionality.
Our model also informs on interactions of SIV Vifs with primate
A3G. SIV Vifs are different from HIV-1 Vif, and it is unknown
whether they adopt a similar protein structure. However, two po-
tential Vif-A3G contact points between African green monkey
and sooty mangabey A3G and Vif proteins of their respective
SIVs were previously described. African green monkey subspe-
cies show variation at A3G position 130 (A3G-130D or A3G-
130H). SIV adaptation in an African green monkey encoding
A3G-130H selected for a specific Y84C Vif change (Compton
et al., 2012, 2013), which is close to the HIV-1 Vif-82D adaptation
to A3G-130R (Figure 5). The HIV-1 Vif-14-SEMQ-17 mutant did
not counteract A3GAGM, suggesting that other polymorphisms
between African green monkey and human A3G could affect
Vif binding (Schro¨felbauer et al., 2006). Macaque A3G contains
a Y59LR variation in the b2-a2 loop, rendering macaque A3G
resistant to SIV from sooty mangabeys (Krupp et al., 2013). SIV
from sooty mangabeys adapted to macaque A3G-Y59LR by
acquiring a Vif-G17E change, which is close to the b2-a2 loop
in our Vif-A3G model. Combined, these data fit in our Vif-A3G
structure model and indicate that the Vif-A3G interface is likely
conserved among primates and their cognate viruses.
Our Vif-A3G structure model will assist in the future generation
of a Vif-A3G co-structure determined by crystallography or NMR,
which is required to identify detailed molecular interactions be-
tween specific Vif and A3G amino acids and their potential struc-
tural rearrangements that occur after Vif binding to A3G. Our
approach to decipher the structural interface can be applied to
other proteins that are difficult to analyze by classical structural
approaches. Furthermore, our model could guide future studies
toward the discovery of small molecule interventions suitable to
inhibit HIV replication by perturbing the Vif-A3G interface.
EXPERIMENTAL PROCEDURES
Amsterdam Cohort Vif Variants
The ACS on HIV infection and AIDS have been conducted in accordance with
the ethical principles set out in the declaration of Helsinki, and all participants
provided written informed consent. The study was approved by the Academic
Medical Center institutional Medical Ethics Committee of the University of
Amsterdam. HIV-1 Vif was cloned from 35 ACS participants at late time points
during the course of infection (Kootstra et al., 2007). Vif was amplified as
described previously (Ooms et al., 2013).
Plasmids
The C-terminally FLAG-tagged Vif expression plasmid encoding NL4-3, LAI,
andHIV-1 subtype Vifs were previously described (Binka et al., 2012). A3Gmu-
tants were C-terminally triple human influenza hemagglutinin (HA) tagged andports 13, 1789–1799, December 1, 2015 ª2015 The Authors 1797
cloned into the ptr600 expression vector as previously described (Ooms et al.,
2012). Point mutagenesis of Vif and A3G was performed by standard overlap-
ping PCR. The Vif Amsterdam Cohort variants were cloned into a modified
NL4-3 molecular clone with the Integrase and Vif open reading frames sepa-
rated (Sakurai et al., 2004; Stern et al., 2010). In addition, a stop codon in frame
with Vpr was inserted after Vif to prevent any production of Vpr.
HIV Single-Cycle Infectivity Assays
For titration experiments, increasing amounts of A3G-3xHA expression plas-
mids (0, 10, 25, 50, and 100 ng) and Vif plasmids (50 ng) were co-transfected
with NL4-3 DVif (500 ng) in 293T cells as previously described (Letko et al.,
2013). In all other assays, 20 ng A3G or 50 ng A3F was used. Culture medium
was replaced 24 hr post-transfection, supernatants were collected 48 hr post-
transfection, and infectivity of analyzed by infecting TZM-bl reporter cells as
previously described (Letko et al., 2013). Average relative infectivity values
and their SDswere calculated from representative triplicate transfections. Pro-
teins were analyzed by western blot as previously described (Letko et al.,
2013).
Co-immunoprecipitation
HEK293T cells were co-transfected with FLAG-Vif expression plasmids
(50 ng), HA-A3G expression plasmid (200 ng), and glutathione S-transferase
stuffer DNA (250 ng) in a 24-well format. Cells were lysed 2 days post-transfec-
tion in a mild lysis buffer (1% Triton X-100 in 1x PBS and EDTA-free protease
inhibitor cocktail; Roche). The cleared lysates were incubated with EZ-View
anti-HA beads (Sigma-Aldrich) at 4C for 2 hr. Beads were washed four times
in mild lysis buffer. Proteins were eluted and analyzed by western blot as pre-
viously described (Letko et al., 2013).
Lentiviral Vectors and Cell Transduction
A3G-P2A-maxGFP cassettes were constructed by overlap PCR and cloned
into the EF1-T2A-puro lentivector backbone (System Biosciences). Lentiviral
vectors were produced in 293T cells according to the manufacturer’s recom-
mendations. SupT1 cells were transduced and placed under puromycin
(0.5 mg/ml) 2 days later. After transduction and selection, cell lysates were
analyzed for A3G expression using an A3G-specific antibody (C17, NIH AIDS
reagents).
HIV-1 Replication Assay
Viral stocks were produced as described (Ooms et al., 2013). The 0.5 3 106
SupT1 cells were infected in triplicate (MOI 0.01) in the presence of 5 mg/ml
polybrene in a 24-well format (1.5 ml). Then, 200 ml of the supernatants were
collected every day, and cultures were replenished with fresh media. After
2 weeks, supernatants were used to infect TZM-bl reporter cells. Error bars
represent SDs of three separate infections.
HIV-1 Forced Evolution
A 25ml flask with 5.0x106 SupT1 cells expressing A3G-130Rwas infected with
NL4-3 (MOI 1.0). Cells were cultured and cellular DNA was isolated using the
DNeasy DNA isolation kit. Proviral Vif was amplified by PCR and sequenced as
previously described (Ooms et al., 2013).
Molecular Docking and Visualization
The structure for A3G amino acids 4–189 was predicted from the A3C crystal
structure (3VOW; Kitamura et al., 2012) and A3G soluble NTD structure (2MZZ;
Kouno et al., 2015) using the SwissModel server. Vif (49NF; Guo et al., 2014)
and A3G-NTD structures were submitted to the ZDock server (Pierce et al.,
2014). Proteins structures were visualized using the PyMOL Molecular
Graphics System (v.1.3, Schro¨dinger). Poisson-Blotzmann electrostatic po-
tential maps for Vif and A3G-NTD structures were produced using the
PDB2PQR server (Dolinsky et al., 2004) and the adaptive poisson-Boltzmann
solver (APBS) toolkit in PyMOL (Baker et al., 2001). A full-length Cullin-5 struc-
ture was predicted from available data for Cullin-1 and Cullin-5 using the
SwissModel server (Goldenberg et al., 2004). Full-length Cullin-5 was then
structurally aligned to the Cullin-5 fragment in the Vif-E3 crystal structure
(49NF) using SwissPDBViewer.1798 Cell Reports 13, 1789–1799, December 1, 2015 ª2015 The AutACCESSION NUMBERS
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